TY - JOUR
T1 - Assessing the prevalence and impact of preserved ratio impaired spirometry in low-income and middle-income countries
T2 - a post-hoc cross-sectional analysis
AU - GECo Study Investigators
AU - Siddharthan, Trishul
AU - Grealis, Kyle
AU - Robertson, Nicole M.
AU - Lu, Min
AU - Liu, Sibei
AU - Pollard, Suzanne L.
AU - Hossen, Shakir
AU - Jackson, Peter
AU - Rykiel, Natalie A.
AU - Wosu, Adaeze C.
AU - Flores-Flores, Oscar
AU - Quaderi, Shumonta A.
AU - Alupo, Patricia
AU - Kirenga, Bruce
AU - Ricciardi, Federico
AU - Barber, Julie A.
AU - Chandyo, Ram K.
AU - Sharma, Arun K.
AU - Das, Santa Kumar
AU - Shresthra, Laxman
AU - Miranda, J. Jaime
AU - Checkley, William
AU - Hurst, John R.
AU - Robertson, Nicole M.
AU - Pollard, Suzanne
AU - A. Quaderi, Shumonta
AU - Barber, Julie
AU - Kumar Das, Santa
AU - Miranda, J. Jaime
AU - Michie, Susan
AU - Anastasiou, Zachos
AU - Wise, Robert A.
AU - Mawanda, Denis
AU - Nassali, Faith
AU - Kalyesubula, Robert
AU - Romani-Huacani, Elisa
AU - Cattamanchi, Adithya
AU - Soares, Marta
AU - Mohan, Sakshi
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2024/9
Y1 - 2024/9
N2 - Background: More than 90% of the morbidity and mortality from chronic respiratory disease occurs in low-income and middle-income countries (LMICs), with substantial economic impact. Preserved ratio impaired spirometry (PRISm) is a prevalent lung function abnormality associated with increased mortality in high-income countries. We aimed to conduct a post-hoc analysis of a cross-sectional study to assess the prevalence of, the risk factors for, and the impact of PRISm in three diverse LMIC settings. Methods: We recruited a random, age-stratified and sex-stratified sample of the population in semi-urban Bhaktapur, Nepal; urban Lima, Peru; and rural Nakaseke, Uganda. Quality-assured post-bronchodilator spirometry was performed to American Thoracic Society standards and PRISm was defined as a forced expiratory volume in one second (FEV1) of less than 80% predicted with a FEV1/forced vital capacity ratio of 0·70 or more. We used t tests and χ2 analyses to assess the relationships between demographic, biometric, and comorbidity variables with PRISm. Multivariable logistic models with random intercept by site were used to estimate odds ratios (ORs) with 95% CIs. Findings: 10 664 participants were included in the analysis, with a mean (SD) age of 56·3 (11·7) years and an equal distribution by sex. The prevalence of PRISm was 2·5% in Peru, 9·1% in Nepal, and 16·0% in Uganda. In multivariable analysis, younger age (OR for each decile of age 0·87, 95% CI 0·82–0·92) and being female (1·37, 1·18–1·58) were associated with increased odds of having PRISm. Biomass exposure was not consistently associated with PRISm across sites. Individuals with PRISm had impairment in respiratory-related quality of life as measured by the St George's Respiratory Questionnaire (OR by decile 1·18, 95% CI 1·10–1·25). Interpretation: The prevalence of PRISm is heterogeneous across LMIC settings and associated with age, female sex, and biomass exposure, a common exposure in LMICs. A diagnosis of PRISm was associated with worse health status when compared with those with normal lung function. Health systems in LMICs should focus on all spirometric abnormalities as opposed to obstruction alone, given the disease burden, reduced quality of life, and size of the undiagnosed population at risk. Funding: Medical Research Council.
AB - Background: More than 90% of the morbidity and mortality from chronic respiratory disease occurs in low-income and middle-income countries (LMICs), with substantial economic impact. Preserved ratio impaired spirometry (PRISm) is a prevalent lung function abnormality associated with increased mortality in high-income countries. We aimed to conduct a post-hoc analysis of a cross-sectional study to assess the prevalence of, the risk factors for, and the impact of PRISm in three diverse LMIC settings. Methods: We recruited a random, age-stratified and sex-stratified sample of the population in semi-urban Bhaktapur, Nepal; urban Lima, Peru; and rural Nakaseke, Uganda. Quality-assured post-bronchodilator spirometry was performed to American Thoracic Society standards and PRISm was defined as a forced expiratory volume in one second (FEV1) of less than 80% predicted with a FEV1/forced vital capacity ratio of 0·70 or more. We used t tests and χ2 analyses to assess the relationships between demographic, biometric, and comorbidity variables with PRISm. Multivariable logistic models with random intercept by site were used to estimate odds ratios (ORs) with 95% CIs. Findings: 10 664 participants were included in the analysis, with a mean (SD) age of 56·3 (11·7) years and an equal distribution by sex. The prevalence of PRISm was 2·5% in Peru, 9·1% in Nepal, and 16·0% in Uganda. In multivariable analysis, younger age (OR for each decile of age 0·87, 95% CI 0·82–0·92) and being female (1·37, 1·18–1·58) were associated with increased odds of having PRISm. Biomass exposure was not consistently associated with PRISm across sites. Individuals with PRISm had impairment in respiratory-related quality of life as measured by the St George's Respiratory Questionnaire (OR by decile 1·18, 95% CI 1·10–1·25). Interpretation: The prevalence of PRISm is heterogeneous across LMIC settings and associated with age, female sex, and biomass exposure, a common exposure in LMICs. A diagnosis of PRISm was associated with worse health status when compared with those with normal lung function. Health systems in LMICs should focus on all spirometric abnormalities as opposed to obstruction alone, given the disease burden, reduced quality of life, and size of the undiagnosed population at risk. Funding: Medical Research Council.
UR - https://www.scopus.com/pages/publications/85201075296
U2 - 10.1016/S2214-109X(24)00233-X
DO - 10.1016/S2214-109X(24)00233-X
M3 - Artículo
C2 - 39151984
AN - SCOPUS:85201075296
SN - 2214-109X
VL - 12
SP - e1498-e1505
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 9
ER -